CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
  • Home
    • About
      • Message from the Editor-in-Chief
      • Mission Statement
      • Editorial Board
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
CardiologyNowNews.org CardiologyNowNews.org
Font ResizerAa
Search
  • Home
    • About
  • News
  • Topics
    • Acute Coronary Syndrome
    • Arrhythmia and Electrophysiology
    • Cardiovascular Imaging
    • Cardiovascular Intervention
    • Cardiovascular Prevention
    • Cerebrovascular Disease
    • Heart Failure
    • Peripheral Vascular Disease
    • Structural Heart Disease
    • Valvular Heart Disease
  • Educational Resources
    • WikiDoc
    • BAIM Grand Rounds
    • Clinical Trial Results
  • ACC
    • ACC 2017
    • ACC 2018
    • ACC 2019
    • ACC 2020
    • ACC 2021
    • ACC 2022
    • ACC 2023
    • ACC 2024
    • ACC 2025
    • ACC 2026
  • AHA
    • AHA 2017
    • AHA 2019
    • AHA 2021
    • AHA 2022
    • AHA 2023
    • AHA 2024
    • AHA 2025
    • AHA 2026
  • ESC
    • ESC 2017
    • ESC 2018
    • ESC 2019
    • ESC 2021
    • ESC 2022
    • ESC 2023
    • ESC 2024
    • ESC 2025
  • SCAI
    • SCAI 2017
    • SCAI 2018
  • Videos
Follow US
AHA 2026News

SRSD216: Lp(a) Remains Lower Through 1 Year After a Single Dose in Phase 1 Study

Basir Gill
Share
6 Min Read
  • SRSD216 (Sirius Therapeutics) is an investigational siRNA against LPA mRNA that is being developed as an annual therapy for high Lp(a).
  • In a phase 1 trial at one center in China, 24 adults aged 18 to 55 with Lp(a) of at least 75 nmol/L were randomized 6:2 within three cohorts to a single dose of SRSD216 (100, 300, or 600 mg) or placebo.
  • Lp(a) fell by up to 95% by day 43 with 300 and 600 mg, and the annualized time-averaged reduction from day 43 to day 365 was 85% in both cohorts.
  • Adverse events, all grade 1 or 2, occurred in 13 of 18 participants on SRSD216 and one of six on placebo.
  • Each dose cohort had six participants on SRSD216; at the same meeting, the Lp(a)HORIZON outcomes trial of pelacarsen found no reduction in cardiovascular events.

Lp(a) remained lower for 1 year after a single subcutaneous dose of SRSD216, an investigational siRNA targeting LPA mRNA, in a phase 1 trial in China. Median time-averaged Lp(a) reductions from day 29 to day 365 were 89.4% with 300 mg and 88.2% with 600 mg. Kausik K. Ray, MD (Imperial College London, United Kingdom), presented the results at the American Heart Association (AHA) Scientific Sessions on November 7, 2026. They have not yet been published in a peer-reviewed journal.

Investigational RNA therapies for Lp(a) are given monthly (antisense oligonucleotides) or every 3 to 6 months (siRNAs) to keep Lp(a) 80% to 95% lower between doses, according to the investigators. SRSD216, from Sirius Therapeutics, is being developed as an annual therapy. Seven-month results from the trial were presented at the American College of Cardiology meeting in March 2026, according to the company.

The dose-escalation part of a double-blind, placebo-controlled, randomized phase 1/2 trial (NCT07172646) enrolled Chinese men and women aged 18 to 55 years with Lp(a) of at least 75 nmol/L. Three cohorts of eight participants were randomized 6:2 to a single subcutaneous dose of SRSD216 (100, 300, or 600 mg) or placebo. The primary endpoint was safety and tolerability, and secondary endpoints were pharmacokinetics and change in Lp(a) from baseline. Lp(a) was measured every 1 to 2 weeks for 2 months and monthly thereafter. Annualized time-averaged reductions were calculated from day 43 to day 365. Sirius Therapeutics is the registered sponsor, and four of the eight authors list Sirius as their affiliation.

The 24 participants were enrolled from April to May 2025 at a single center and completed 1-year follow-up.Their mean age was 37.6 years, 54.2% were men, and mean baseline Lp(a) was 107 nmol/L.

Treatment-emergent adverse events occurred in 13 of the 18 participants on SRSD216 and one of six on placebo. By dose, the numbers were 5 of 6 at 100 mg, 3 of 6 at 300 mg, and 5 of 6 at 600 mg. All were grade 1 or 2, and no serious adverse events, deaths, or withdrawals for adverse events occurred. Injection-site reactions occurred in 4 of the 18 participants on SRSD216. Two participants on SRSD216 had concurrent ALT and AST elevations without a rise in bilirubin, and both resolved during follow-up. SRSD216 reached peak concentration 4 to 12 hours after the dose and had a half-life of about 6 hours, and exposure increased generally in proportion to dose.

Lp(a) fell by up to 95% by day 43 in the 300-mg and 600-mg cohorts. The annualized time-averaged reduction from day 43 to day 365 was 85% in both cohorts. Within-person Lp(a) levels varied little from month to month over the year, the investigators reported.

Each dose group had six participants on SRSD216, all from one center, so the results are limited in precision and generalizability. Reductions on day 365 were smaller than at day 43 in all three dose groups, and placebo values are shown only through day 85. The investigators proposed annual dosing at 600 mg; the 300-mg dose produced the same annualized reduction in this trial.

Kylo-11, another siRNA against LPA, was also tested at a single site in China in adults aged 18 to 55 years (Sarraju et al., Lancet, 2026). One dose produced median Lp(a) reductions of 53% to 97% at 48 weeks across cohorts given 9 to 600 mg. At this year’s AHA meeting, the Lp(a)HORIZON outcomes trial showed that pelacarsen, a monthly antisense oligonucleotide, lowered Lp(a) by 78.4% at 12 months in patients with cardiovascular disease. Major adverse cardiovascular events occurred in 12.3% of 4,157 patients on pelacarsen and 12.1% of 4,165 on placebo (hazard ratio 1.02; 95% CI 0.90 to 1.15). SRSD216 is being tested in broader populations, the investigators wrote. Sirius announced in December 2025 that it had dosed the first patient in a phase 2 trial.

TAGGED:AHA 2026FeaturedNews
Share This Article
Copy Link Print
CardiologyNowNews.org CardiologyNowNews.org
Copyright - CardiologyNowNews
  • Contact Us
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?